HC Wainwright Equities Analysts Decrease Earnings Estimates for BioNTech SE (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTX - Free Report) - Stock analysts at HC Wainwright dropped their FY2024 earnings per share (EPS) estimates for BioNTech in a research report issued to clients and investors on Tuesday, August 27th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($3.71) per share for the year, down from their prior forecast of ($3.66). HC Wainwright currently has a "Buy" rating and a $113.00 price target on the stock. The consensus estimate for BioNTech's current full-year earnings is ($2.04) per share. HC Wainwright also issued estimates for BioNTech's Q1 2025 earnings at ($2.39) EPS, Q2 2025 earnings at ($2.40) EPS and FY2025 earnings at ($3.15) EPS.

A number of other research analysts have also recently commented on BNTX. JPMorgan Chase & Co. lowered their target price on BioNTech from $94.00 to $91.00 and set an "underweight" rating for the company in a research note on Thursday, August 15th. HSBC raised shares of BioNTech from a "hold" rating to a "buy" rating in a research report on Friday, August 2nd. Evercore ISI initiated coverage on shares of BioNTech in a report on Tuesday, May 14th. They set an "inline" rating and a $100.00 target price for the company. BMO Capital Markets dropped their price target on BioNTech from $123.00 to $122.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 7th. Finally, Hsbc Global Res raised BioNTech from a "hold" rating to a "strong-buy" rating in a report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, BioNTech presently has a consensus rating of "Moderate Buy" and a consensus price target of $109.09.

BioNTech Stock Down 0.7 %

BioNTech stock traded down $0.60 during trading hours on Thursday, hitting $87.60. 466,969 shares of the stock traded hands, compared to its average volume of 694,973. BioNTech has a one year low of $76.53 and a one year high of $125.83. The firm's 50-day moving average price is $83.92 and its two-hundred day moving average price is $89.39. The company has a current ratio of 11.38, a quick ratio of 11.16 and a debt-to-equity ratio of 0.01. The company has a market cap of $20.82 billion, a PE ratio of 176.40 and a beta of 0.23.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing analysts' consensus estimates of ($2.02) by ($1.34). BioNTech had a net margin of 4.01% and a return on equity of 0.55%. The company had revenue of $128.70 million for the quarter, compared to the consensus estimate of $134.98 million. During the same period in the previous year, the firm posted ($0.86) EPS. The company's revenue for the quarter was down 23.3% on a year-over-year basis.

Institutional Trading of BioNTech

Institutional investors have recently made changes to their positions in the stock. Harding Loevner LP bought a new position in BioNTech in the fourth quarter valued at about $410,984,000. Candriam S.C.A. lifted its stake in shares of BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company's stock worth $46,526,000 after purchasing an additional 418,695 shares during the period. Point72 Asset Management L.P. lifted its stake in shares of BioNTech by 283.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company's stock worth $37,103,000 after purchasing an additional 341,311 shares during the period. Primecap Management Co. CA boosted its holdings in shares of BioNTech by 2.8% in the fourth quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company's stock worth $502,735,000 after buying an additional 131,490 shares during the last quarter. Finally, SG Americas Securities LLC increased its holdings in BioNTech by 610.5% during the first quarter. SG Americas Securities LLC now owns 70,143 shares of the company's stock valued at $6,471,000 after buying an additional 60,270 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.